The objective of a study by Sakhaee et al. (A-22) was to ascertain body content of aluminum (A1)

noninvasively using the increment in serum and urinary Al following the intravenous administration of deferoxamine (DFO) in patients with kidney stones and osteoporotic women undergoing longterm treatment with potassium citrate (K3Cit) or tricalcium dicitrate (Ca3Cit2), respectively. Subjects consisted of 10 patients with calcium nephrolithiasis and five patients with osteoporosis who were maintained on potassium citrate or calcium citrate for 2–8 years, respectively, plus 16 normal volunteers without a history of regular aluminum-containing antacid use. Among the data collected were the following 24-hour urinary aluminum excretion measurements ð Þ mg=day before (PRE) and after (POST) 2-hour infusion of DFO.

Group PRE POST Group PRE POST Control 41.04 135.00 Control 9.39 12.32 Control 70.00 95.20 Control 10.72 13.42 Control 42.60 74.00 Control 16.48 17.40 Control 15.48 42.24 Control 10.20 14.20 Control 26.90 104.30 Control 11.40 20.32 Control 16.32 66.90 Control 8.16 12.80 Control 12.80 10.68 Control 14.80 62.00 Control 68.88 46.48 Patient 15.20 27.15 Control 25.50 73.80 Patient 8.70 38.72 Patient 0.00 14.16 Patient 5.52 7.84 Patient 2.00 20.72 Patient 13.28 31.70 Patient 4.89 15.72 Patient 3.26 17.04 Patient 25.90 52.40 Patient 29.92 151.36 Patient 19.35 35.70 Patient 15.00 61.38 Group PRE POST Group PRE POST Patient 4.88 70.20 Patient 36.80 142.45 Patient 42.75 86.25 Source: Data provided courtesy of Dr. Khashayar Sakhaee.